ArticleInfection and immunity1997
A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity.
Article in Infection and immunity, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Exploring the structural basis and functional immunodynamics of immunoglobulin M in host defense against fungal pathogens.Frontiers in immunology · 2025Review
- The Role of B-Cells and Antibodies againstVaccines · 2021Review
- Design of a mimotope-peptide based double epitope vaccine against disseminated candidiasis.Vaccine · 2019Article
- The protective role of immunoglobulins in fungal infections and inflammation.Seminars in immunopathology · 2015Review
- Emerging drugs and vaccines for candidemia.Mycoses · 2014Review
- Characterization of Scedosporium apiospermum glucosylceramides and their involvement in fungal development and macrophage functions.PloS one · 2014Article
- Anticandidal immunity and vaginitis: novel opportunities for immune intervention.Infection and immunity · 2007Review
- A fungicidal monoclonal antibody protects against murine invasive candidiasis.Infection and immunity · 2006Article
- Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice.Infection and immunity · 2006Article
- Surface hydrophobicity changes of two Candida albicans serotype B mnn4delta mutants.Eukaryotic cell · 2005Article
- Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.Clinical microbiology reviews · 2004Review
- Enhanced phagocytosis of Candida species mediated by opsonization with a recombinant human antibody single-chain variable fragment.Infection and immunity · 2003Article
- Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody.Infection and immunity · 2000Article
- Non-serum-dependent chemotactic factors produced by Candida albicans stimulate chemotaxis by binding to the formyl peptide receptor on neutrophils and to an unknown receptor on macrophages.Infection and immunity · 1999Article
- Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans.Infection and immunity · 1998Article
- A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.Infection and immunity · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A monoclonal antibody (MAb) to Candida albicans (MAb B6.1) that protects against candidiasis and the nonprotective MAb B6 were compared for ability to support neutrophil (polymorphonuclear leukocyte [PMN]) candidacidal activity. Both MAbs are immunoglobulin M, and each recognizes distinct C. albicans mannan cell wall determinants. PMN candidacidal activity was assessed by transmission electron microscopy and by an in vitro killing assay. The results indicated that MAb B6.1, but not MAb B6, enhances ingestion and killing of yeast cells by PMN in the presence of serum complement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.